Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.

ABSTRACT:

Background

Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages. The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently unclear.

Methods

Patients with metastatic or unresectable UM treated with ipilimumab in combination with a PD-1 inhibitor were collected from 16 German skin cancer centers. Patient records of 64 cases were analyzed for response, progression-free survival (PFS), overall survival (OS), and safety. Clinical parameters and serum biomarkers associated with OS and treatment response were determined with Cox regression modelling and logistic regression.

Results

The best overall response rate to combined checkpoint blockade was 15.6% with 3.1 and 12.5% complete and

SUBMITTER: Heppt MV 

PROVIDER: S-EPMC6854774 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature